-
1
-
-
33644777800
-
A trimeric anti-HER2/neu ScFv and tumor necrosis factor-Alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia
-
Huang TH, Morrison SL. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-Alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia. J Pharmacol Exp Ther. 2006;316:983-991
-
(2006)
J Pharmacol Exp Ther
, vol.316
, pp. 983-991
-
-
Huang, T.H.1
Morrison, S.L.2
-
2
-
-
0034638917
-
Overexpression of ErbB2 in cancer and ErbB2-Targeting strategies
-
Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-Targeting strategies. Oncogene. 2000;19:6115-6121
-
(2000)
Oncogene
, vol.19
, pp. 6115-6121
-
-
Yu, D.1
Hung, M.C.2
-
3
-
-
33645688204
-
HER2-positive circulating tumor cells indicate poor clinical outcome in stage i to III breast cancer patients
-
Wulfing P, Borchard J, Buerger H, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. 2006;12: 1715-1720
-
(2006)
Clin Cancer Res
, vol.12
, pp. 1715-1720
-
-
Wulfing, P.1
Borchard, J.2
Buerger, H.3
-
4
-
-
0032078876
-
ERBB2 oncogene in human breast cancer and its clinical significance
-
Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34:791-808
-
(1998)
Eur J Cancer
, vol.34
, pp. 791-808
-
-
Revillion, F.1
Bonneterre, J.2
Peyrat, J.P.3
-
5
-
-
0032982818
-
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
-
Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 1999;79: 1220-1226
-
(1999)
Br J Cancer
, vol.79
, pp. 1220-1226
-
-
Houston, S.J.1
Plunkett, T.A.2
Barnes, D.M.3
-
6
-
-
33750699642
-
A phase i study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
-
Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106-6115
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6106-6115
-
-
Kershaw, M.H.1
Westwood, J.A.2
Parker, L.L.3
-
7
-
-
50849123421
-
HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target
-
Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-1529
-
(2008)
Ann Oncol
, vol.19
, pp. 1523-1529
-
-
Gravalos, C.1
Jimeno, A.2
-
9
-
-
84874849358
-
Erbb2 overexpression in uterine serous cancer: A molecular target for trastuzumab therapy
-
Elsahwi KS, Santin AD. erbB2 overexpression in uterine serous cancer: A molecular target for trastuzumab therapy. Obstet Gynecol Int. 2011;128295:5
-
(2011)
Obstet Gynecol Int
, vol.5
, pp. 128295
-
-
Elsahwi, K.S.1
Santin, A.D.2
-
10
-
-
84874928725
-
Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: A possible target for immunotherapy
-
Zuhur SS, Tanik C, Erol RS, et al. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: A possible target for immunotherapy. Turk Neurosurg. 2013;23:55-60
-
(2013)
Turk Neurosurg
, vol.23
, pp. 55-60
-
-
Zuhur, S.S.1
Tanik, C.2
Erol, R.S.3
-
11
-
-
23844510061
-
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-Amplified breast cancer
-
Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-Amplified breast cancer. Invest New Drugs. 2005;23:391-409
-
(2005)
Invest New Drugs
, vol.23
, pp. 391-409
-
-
Yeon, C.H.1
Pegram, M.D.2
-
12
-
-
33748525213
-
Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer
-
Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist. 2006;11:857-867
-
(2006)
Oncologist
, vol.11
, pp. 857-867
-
-
Gonzalez-Angulo, A.M.1
Hortobagyi, G.N.2
Esteva, F.J.3
-
13
-
-
42149131528
-
Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
-
Osako T, Ito Y, Takahashi S, et al. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62:159-164
-
(2008)
Cancer Chemother Pharmacol
, vol.62
, pp. 159-164
-
-
Osako, T.1
Ito, Y.2
Takahashi, S.3
-
14
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl JMed. 2001;344:783-792
-
(2001)
N Engl JMed
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
15
-
-
33947165711
-
Phage display of chelating recombinant antibody libraries
-
Wright MJ, Deonarain MP. Phage display of chelating recombinant antibody libraries. Mol Immunol. 2007;44:2860-2869
-
(2007)
Mol Immunol
, vol.44
, pp. 2860-2869
-
-
Wright, M.J.1
Deonarain, M.P.2
-
16
-
-
70349342731
-
Adoptive immunotherapy for cancer: The next generation of gene-engineered immune cells
-
Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: The next generation of gene-engineered immune cells. Tissue Antigens. 2009;74:277-289
-
(2009)
Tissue Antigens
, vol.74
, pp. 277-289
-
-
Berry, L.J.1
Moeller, M.2
Darcy, P.K.3
-
17
-
-
33846215917
-
Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors
-
Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer. 2007;109:170-179
-
(2007)
Cancer
, vol.109
, pp. 170-179
-
-
Beckman, R.A.1
Weiner, L.M.2
Davis, H.M.3
-
18
-
-
0035987985
-
Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients
-
Schule J, Bergkvist L, Hakansson L, et al. Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res Treat. 2002;74:33-40
-
(2002)
Breast Cancer Res Treat
, vol.74
, pp. 33-40
-
-
Schule, J.1
Bergkvist, L.2
Hakansson, L.3
-
19
-
-
0036307836
-
Clinical significance of poor CD3 response in head and neck cancer
-
Shibuya TY, Nugyen N, McLaren CE, et al. Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res. 2002;8:745-751
-
(2002)
Clin Cancer Res
, vol.8
, pp. 745-751
-
-
Shibuya, T.Y.1
Nugyen, N.2
McLaren, C.E.3
-
20
-
-
2342655822
-
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes
-
Wang J, Press OW, Lindgren CG, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther. 2004;9:577-586
-
(2004)
Mol Ther
, vol.9
, pp. 577-586
-
-
Wang, J.1
Press, O.W.2
Lindgren, C.G.3
-
21
-
-
12344276425
-
Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor
-
Schirrmann T, Pecher G. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res. 2005;29:301-306
-
(2005)
Leuk Res
, vol.29
, pp. 301-306
-
-
Schirrmann, T.1
Pecher, G.2
-
22
-
-
0035576250
-
Tumorspecific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule
-
Hombach A, Wieczarkowiecz A, Marquardt T, et al. Tumorspecific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol. 2001;167:6123-6131
-
(2001)
J Immunol
, vol.167
, pp. 6123-6131
-
-
Hombach, A.1
Wieczarkowiecz, A.2
Marquardt, T.3
-
23
-
-
84906086053
-
Construction of fusion gene anti-erbB2-scFv-Fc-CD28-CD3 (z) and expression in eukaryotic cell
-
Sui W, Su S, Hu W, et al. Construction of fusion gene anti-erbB2-scFv-Fc-CD28-CD3 (z) and expression in eukaryotic cell. Chin J Cell Biol. 2010;32:1-7
-
(2010)
Chin J Cell Biol
, vol.32
, pp. 1-7
-
-
Sui, W.1
Su, S.2
Hu, W.3
-
24
-
-
77951684508
-
Shaping successful and unsuccessful CD8 T cell responses following infection
-
Cox MA, Zajac AJ. Shaping successful and unsuccessful CD8 T cell responses following infection. J Biomed Biotechnol. 2010;159152:12
-
(2010)
J Biomed Biotechnol
, vol.12
, pp. 159152
-
-
Cox, M.A.1
Zajac, A.J.2
-
25
-
-
10744225529
-
Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor
-
Gyobu H, Tsuji T, Suzuki Y, et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res. 2004;64:1490-1495
-
(2004)
Cancer Res
, vol.64
, pp. 1490-1495
-
-
Gyobu, H.1
Tsuji, T.2
Suzuki, Y.3
-
26
-
-
27644445691
-
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection
-
Moeller M, Haynes NM, Kershaw MH, et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood. 2005; 106:2995-3003
-
(2005)
Blood
, vol.106
, pp. 2995-3003
-
-
Moeller, M.1
Haynes, N.M.2
Kershaw, M.H.3
-
27
-
-
0037456367
-
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
-
Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852-856
-
(2003)
Nature
, vol.421
, pp. 852-856
-
-
Janssen, E.M.1
Lemmens, E.E.2
Wolfe, T.3
-
28
-
-
33645451483
-
Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors
-
Baum C, Kustikova O, Modlich U, et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther. 2006;17:253-263
-
(2006)
Hum Gene Ther
, vol.17
, pp. 253-263
-
-
Baum, C.1
Kustikova, O.2
Modlich, U.3
-
29
-
-
33646887376
-
Genotoxicity of retroviral integration in hematopoietic cells
-
Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006;13:1031-1049
-
(2006)
Mol Ther
, vol.13
, pp. 1031-1049
-
-
Nienhuis, A.W.1
Dunbar, C.E.2
Sorrentino, B.P.3
-
30
-
-
75449087525
-
Electro-mediated gene transfer and expression are controlled by the life-Time of DNA/ membrane complex formation
-
Faurie C, Rebersek M, Golzio M, et al. Electro-mediated gene transfer and expression are controlled by the life-Time of DNA/ membrane complex formation. J Gene Med. 2010;12:117-125
-
(2010)
J Gene Med
, vol.12
, pp. 117-125
-
-
Faurie, C.1
Rebersek, M.2
Golzio, M.3
-
31
-
-
77649160212
-
Comparative transfection of DNA into primary and transformed mammalian cells from different lineages
-
Maurisse R, De Semir D, Emamekhoo H, et al. Comparative transfection of DNA into primary and transformed mammalian cells from different lineages. BMC Biotechnol. 2010;10:9-17
-
(2010)
BMC Biotechnol
, vol.10
, pp. 9-17
-
-
Maurisse, R.1
De Semir, D.2
Emamekhoo, H.3
-
32
-
-
84934439329
-
Electroporation-based gene therapy: Recent evolution in the mechanism description and technology developments
-
Mir LM. Electroporation-based gene therapy: Recent evolution in the mechanism description and technology developments. Methods Mol Biol. 2014;1121:3-23
-
(2014)
Methods Mol Biol
, vol.1121
, pp. 3-23
-
-
Mir, L.M.1
-
33
-
-
84934443007
-
Electroporation formulation for cell therapy
-
Hu J, Li S. Electroporation formulation for cell therapy. Methods Mol Biol. 2014;1121:55-60
-
(2014)
Methods Mol Biol
, vol.1121
, pp. 55-60
-
-
Hu, J.1
Li, S.2
-
34
-
-
33646398347
-
Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma
-
Cooper LJ, Ausubel L, Gutierrez M, et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy. 2006;8:105-117
-
(2006)
Cytotherapy
, vol.8
, pp. 105-117
-
-
Cooper, L.J.1
Ausubel, L.2
Gutierrez, M.3
-
35
-
-
34548485103
-
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains
-
Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007;18:712-725
-
(2007)
Hum Gene Ther
, vol.18
, pp. 712-725
-
-
Wang, J.1
Jensen, M.2
Lin, Y.3
-
36
-
-
58149477054
-
Effect of trehalose on protein structure
-
Jain NK, Roy I. Effect of trehalose on protein structure. Protein Sci. 2009;18:24-36
-
(2009)
Protein Sci
, vol.18
, pp. 24-36
-
-
Jain, N.K.1
Roy, I.2
-
37
-
-
77950853704
-
Activation of caspases and apoptosis in response to low-voltage electric pulses
-
Matsuki N, Takeda M, Ishikawa T, et al. Activation of caspases and apoptosis in response to low-voltage electric pulses. Oncol Rep. 2010;23:1425-1433
-
(2010)
Oncol Rep
, vol.23
, pp. 1425-1433
-
-
Matsuki, N.1
Takeda, M.2
Ishikawa, T.3
-
38
-
-
38349177530
-
Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy
-
Meehan KR, Wu J, Webber SM, et al. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. Cytotherapy. 2008;10:30-37
-
(2008)
Cytotherapy
, vol.10
, pp. 30-37
-
-
Meehan, K.R.1
Wu, J.2
Webber, S.M.3
-
39
-
-
0033655529
-
Human T lymphocyte genetic modification with naked DNA
-
Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther. 2000;1: 49-55
-
(2000)
Mol Ther
, vol.1
, pp. 49-55
-
-
Jensen, M.C.1
Clarke, P.2
Tan, G.3
-
40
-
-
18544408628
-
A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase i trial
-
Alvarez RD, Barnes MN, Gomez-Navarro J, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial. Clin Cancer Res. 2000;6:3081-3087
-
(2000)
Clin Cancer Res
, vol.6
, pp. 3081-3087
-
-
Alvarez, R.D.1
Barnes, M.N.2
Gomez-Navarro, J.3
-
41
-
-
33745070631
-
Antibodydependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes
-
Clemenceau B, Congy-Jolivet N, Gallot G, et al. Antibodydependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood. 2006;107:4669-4677
-
(2006)
Blood
, vol.107
, pp. 4669-4677
-
-
Clemenceau, B.1
Congy-Jolivet, N.2
Gallot, G.3
-
42
-
-
0036196127
-
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv
-
Arafat WO, Gomez-Navarro J, Buchsbaum DJ, et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther. 2002;9:256-262
-
(2002)
Gene Ther
, vol.9
, pp. 256-262
-
-
Arafat, W.O.1
Gomez-Navarro, J.2
Buchsbaum, D.J.3
-
43
-
-
0041308272
-
Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma
-
Barker SD, Dmitriev IP, Nettelbeck DM, et al. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther. 2003;10:1198-1204
-
(2003)
Gene Ther
, vol.10
, pp. 1198-1204
-
-
Barker, S.D.1
Dmitriev, I.P.2
Nettelbeck, D.M.3
-
44
-
-
16644364683
-
Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene
-
Guo MG, Jiang MH, Yang Q, et al. Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene. Zhonghua Yi Xue Za Zhi. 2004;84:1147-1151
-
(2004)
Zhonghua Yi Xue Za Zhi
, vol.84
, pp. 1147-1151
-
-
Guo, M.G.1
Jiang, M.H.2
Yang, Q.3
-
45
-
-
33745818353
-
High efficient mammalian expression and secretion of a functional humanized single-chain Fv/human interleukin-2 molecules
-
Shen YC, Wang XH, Wang XM, et al. High efficient mammalian expression and secretion of a functional humanized single-chain Fv/human interleukin-2 molecules. World J Gastroenterol. 2006;12:3859-3865
-
(2006)
World J Gastroenterol
, vol.12
, pp. 3859-3865
-
-
Shen, Y.C.1
Wang, X.H.2
Wang, X.M.3
-
46
-
-
32544449156
-
Gene expression and function study of fusion immunotoxin anti-Her-2-scFv-SEC2 in Escherichia coli
-
Ming-Kai X, Cheng-Gang Z. Gene expression and function study of fusion immunotoxin anti-Her-2-scFv-SEC2 in Escherichia coli. Appl Microbiol Biotechnol. 2006;70:78-84
-
(2006)
Appl Microbiol Biotechnol
, vol.70
, pp. 78-84
-
-
Ming-Kai, X.1
Cheng-Gang, Z.2
-
47
-
-
32544431927
-
Specific delivery of corroles to cells via noncovalent conjugates with viral proteins
-
Agadjanian H, Weaver JJ, Mahammed A, et al. Specific delivery of corroles to cells via noncovalent conjugates with viral proteins. Pharm Res. 2006;23:367-377
-
(2006)
Pharm Res
, vol.23
, pp. 367-377
-
-
Agadjanian, H.1
Weaver, J.J.2
Mahammed, A.3
-
48
-
-
49149106425
-
Barnase as a new therapeutic agent triggering apoptosis in human cancer cells
-
Edelweiss E, Balandin TG, Ivanova JL, et al. Barnase as a new therapeutic agent triggering apoptosis in human cancer cells. PLoS One. 2008;3:e2434
-
(2008)
PLoS One
, vol.3
-
-
Edelweiss, E.1
Balandin, T.G.2
Ivanova, J.L.3
-
49
-
-
11144238604
-
Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format
-
Shahied LS, Tang Y, Alpaugh RK, et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004;279:53907-53914
-
(2004)
J Biol Chem
, vol.279
, pp. 53907-53914
-
-
Shahied, L.S.1
Tang, Y.2
Alpaugh, R.K.3
-
50
-
-
25844517682
-
Phase i clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
-
von Minckwitz G, Harder S, Hovelmann S, et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005;7: R617-R626
-
(2005)
Breast Cancer Res
, vol.7
-
-
Von Minckwitz, G.1
Harder, S.2
Hovelmann, S.3
-
51
-
-
0035135433
-
Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells
-
Marshall KW, Marks JD. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells. J Immunother. 2001;24:27-36
-
(2001)
J Immunother
, vol.24
, pp. 27-36
-
-
Marshall, K.W.1
Marks, J.D.2
-
52
-
-
13844296952
-
A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2
-
Biburger M, Weth R, Wels WS. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. J Mol Biol. 2005;346:1299-1311
-
(2005)
J Mol Biol
, vol.346
, pp. 1299-1311
-
-
Biburger, M.1
Weth, R.2
Wels, W.S.3
-
53
-
-
0037441593
-
T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect
-
Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B- lineage leukemia effect. Blood. 2003;101: 1637-1644
-
(2003)
Blood
, vol.101
, pp. 1637-1644
-
-
Cooper, L.J.1
Topp, M.S.2
Serrano, L.M.3
-
54
-
-
0038246383
-
Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy
-
Jensen MC, Cooper LJ, Wu AM, et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy. 2003;5:131-138
-
(2003)
Cytotherapy
, vol.5
, pp. 131-138
-
-
Jensen, M.C.1
Cooper, L.J.2
Wu, A.M.3
-
55
-
-
47649130059
-
Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene
-
Yu K, Hu Y, Tan Y, et al. Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk Lymphoma. 2008;49:1368-1373
-
(2008)
Leuk Lymphoma
, vol.49
, pp. 1368-1373
-
-
Yu, K.1
Hu, Y.2
Tan, Y.3
-
56
-
-
50549096284
-
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
-
Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261-2271
-
(2008)
Blood
, vol.112
, pp. 2261-2271
-
-
Till, B.G.1
Jensen, M.C.2
Wang, J.3
-
57
-
-
0036137615
-
Human T-lymphocyte cytotoxicity and proliferation Directed by a single chimeric TCRzeta/CD28 receptor
-
Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation Directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 2002;20:70-75
-
(2002)
Nat Biotechnol
, vol.20
, pp. 70-75
-
-
Maher, J.1
Brentjens, R.J.2
Gunset, G.3
-
58
-
-
0037454757
-
Activation of T cells via tumor antigen specific chimeric receptors: The role of the intracellular signaling domain
-
Losch FO, Muller R, Mutschler B, et al. Activation of T cells via tumor antigen specific chimeric receptors: The role of the intracellular signaling domain. Int J Cancer. 2003;103: 399-407
-
(2003)
Int J Cancer
, vol.103
, pp. 399-407
-
-
Losch, F.O.1
Muller, R.2
Mutschler, B.3
-
59
-
-
0033692892
-
Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions
-
Patel SD, Ge Y, Moskalenko M, et al. Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions. J Immunother. 2000;23:661-668
-
(2000)
J Immunother
, vol.23
, pp. 661-668
-
-
Patel, S.D.1
Ge, Y.2
Moskalenko, M.3
-
60
-
-
69249248185
-
Genetically engineered T cells to target EGFRvIII expressing glioblastoma
-
Bullain SS, Sahin A, Szentirmai O, et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol. 2009;94:373-382
-
(2009)
J Neurooncol
, vol.94
, pp. 373-382
-
-
Bullain, S.S.1
Sahin, A.2
Szentirmai, O.3
-
61
-
-
0036047663
-
Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis
-
Ren-Heidenreich L, Mordini R, Hayman GT, et al. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol Immunother. 2002;51:417-423
-
(2002)
Cancer Immunol Immunother
, vol.51
, pp. 417-423
-
-
Ren-Heidenreich, L.1
Mordini, R.2
Hayman, G.T.3
-
62
-
-
0031927364
-
Crossregulation between Th1 and Th2 cells
-
Morel PA, Oriss TB. Crossregulation between Th1 and Th2 cells. Crit Rev Immunol. 1998;18:275-303
-
(1998)
Crit Rev Immunol
, vol.18
, pp. 275-303
-
-
Morel, P.A.1
Oriss, T.B.2
-
63
-
-
0030022782
-
Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the longterm survival of memory cells
-
Mueller DL, Seiffert S, Fang W, et al. Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells. A model for the longterm survival of memory cells. J Immunol. 1996;156: 1764-1771
-
(1996)
J Immunol
, vol.156
, pp. 1764-1771
-
-
Mueller, D.L.1
Seiffert, S.2
Fang, W.3
|